Biotech News
GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers
Promising efficacy and safety profile supports start of five pivotal phase III trials in 2026.
Related news
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
GSKGSK plc2026-07-10 11:00 EST
GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
RVMDRevolution Medicines2026-07-02 12:00 EST
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
RVMDRevolution Medicines2026-06-24 23:31 EST
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
KYMRKymera2026-06-12 11:00 EST
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
ELVNEnliven Therapeutics2026-06-11 12:00 EST
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
COGTCogent Biosciences2026-06-30 12:00 EST
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
NTLAIntellia2026-06-13 11:30 EST
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
BMEABiomea Fusion2026-06-05 23:32 EST
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
GSK plc
Global Biopharmaceutical Portfolio GSK is a global biopharmaceutical company operating across Specialty Medicines, Vaccines, and General Medicines. Its commercial portfolio spans HIV, oncology, respiratory and immuno-inflammation, vaccines, and established medicines, supported by a growing late-stage pipeline and externally sourced...
Recent company news
GSKGSK plc2026-08-24 07:01 EST
Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer
GSKGSK plc2026-08-24 07:00 EST
Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
Stock data
- Close
- 52.41 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States